NEW YORK ( TheStreet) -- Myriad Genetics (Nasdaq: MYGN) is trading at unusually high volume Monday with 2.1 million shares changing hands. It is currently at 4.3 times its average daily volume and trading up 59 cents (+2.6%) at $23.37 as of 3:40 p.m. ET. Myriad has a market cap of $1.9 billion and is part of the services sector and diversified services industry. Shares are up 9.7% year to date as of the close of trading on Friday. Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of novel predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States. The company has a P/E ratio of 18.8, below the average diversified services industry P/E ratio of 19.4 and above the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates Myriad as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, reasonable valuation levels and growth in earnings per share. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full Myriad Ratings Report. See all heavy volume stocks in our stocks moving on unusual volume list or get investment ideas from our investment research center. Interested in other stocks that are rising on unusually high volume? Get free SMS text alerts sent to you when the action happens by texting HVUP to 95370 or select from multiple alert options.